21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
17:22 , Apr 19, 2019 |  BC Week In Review  |  Company News

FDA expands Keytruda's NSCLC indications

Merck said FDA approved Keytruda pembrolizumab as monotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC) and advanced NSCLC in patients who are not candidates for surgical resection or definitive chemoradiation. Patients' tumors...
17:57 , Mar 22, 2019 |  BC Week In Review  |  Company News

EC approves Keytruda for first-line NSCLC regardless of PD-L1 expression

Merck & Co. said the European Commission approved Keytruda pembrolizumab plus carboplatin and either paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic, squamous non-small cell lung cancer regardless of PD-L1 expression. Merck & Co....
18:23 , Nov 30, 2018 |  BC Week In Review  |  Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
00:01 , Nov 22, 2018 |  BC Extra  |  Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
19:56 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

FDA approves Keytruda for first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA approved Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression. The sBLA was under Priority...
17:41 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange on Oct. 24, raising HK$3.3 billion ($421 million). Innovent sold 236.4 million shares at HK$13.98, near the top...
21:05 , Oct 24, 2018 |  BC Extra  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange, raising HK$3.3 billion ($421 million), according to a source close to the deal who asked not to be...
19:32 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Reports say Innovent seeking $422M IPO in Hong Kong

Innovent Biologics Inc. (Suzhou, China) did not respond to inquiries regarding reports that the company is seeking to raise $422 million in an IPO on the Hong Kong stock exchange, which would value the company...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Tecentriq combo leads to median OS of 18.1 months at interim analysis of Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy did not show a significant improvement on the co-primary endpoint of overall survival (OS) compared with chemotherapy alone at...